BioLight Life Sciences Ltd. (IL:BOLT)
:BOLT
BOLT Stock Chart & Stats
371.40
-0.16(-2.50%)
At close: 4:00 PM EST
371.40
-0.16(-2.50%)
Day’s Range― - ―
52-Week Range254.10 - 671.00
Previous CloseN/A
Volume1.67K
Average Volume (3M)11.86K
Market Cap
₪25.25M
Enterprise Value11.40M
Total Cash (Recent Filing)₪23.65M
Total Debt (Recent Filing)₪772.00K
Price to Earnings (P/E)―
Beta0.61
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,079,270
10 Day Avg. Volume7,448
30 Day Avg. Volume11,863
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.61
Price to Sales (P/S)0.00
P/FCF Ratio-1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Debt ProfileVery low debt materially reduces refinancing and solvency risk, providing structural financial flexibility. Over a multi-month horizon this lowers fixed financing costs and preserves optionality for R&D timelines, partnerships, or staged funding without immediate debt pressure.
Material Equity Cushion RemainsDespite erosion, the company still holds a multi-million equity buffer that can fund near-term operations or R&D progress. This capital cushion affords time to advance pre-commercial assets, pursue partnerships, or structure financing from a position that is not immediately insolvent.
R&D-focused, Pre-commercial Business ModelA concentrated R&D orientation is durable: successful clinical or product development can create high-margin, scalable revenue streams later. Structurally, an R&D-led pipeline creates optionality for licensing, partnerships, or milestone revenue if programs progress, providing long-term upside.
Bears Say
Revenue Fell To Zero In 2025Zero reported revenue is a fundamental weakness: it indicates no current commercial traction and prevents internal funding of operations. Without sustainable sales, the company must rely on external capital or deals, raising execution and dilution risk over the coming months.
Persistent Negative Operating Cash FlowOngoing cash burn of roughly -9.5M to -11.4M annually is structurally significant: losses translate into real cash outflows, creating recurring financing needs. Over a 2–6 month horizon this pressure increases the probability of dilutive financing or constrained R&D progress if capital access tightens.
Sustained Operating And Net Losses; Eroding EquityRepeated operating and net losses have materially eroded shareholders' equity and produced negative returns on equity. This trend undermines balance-sheet resilience and heightens solvency concerns unless revenue scale or meaningful cost restructuring occurs, threatening long-term viability.
BOLT FAQ
What was BioLight Life Sciences Ltd.’s price range in the past 12 months?
BioLight Life Sciences Ltd. lowest stock price was 254.10 and its highest was 671.00 in the past 12 months.
What is BioLight Life Sciences Ltd.’s market cap?
BioLight Life Sciences Ltd.’s market cap is ₪25.25M.
When is BioLight Life Sciences Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BioLight Life Sciences Ltd.’s earnings last quarter?
Currently, no data Available
Is BioLight Life Sciences Ltd. overvalued?
According to Wall Street analysts BioLight Life Sciences Ltd.’s price is currently Overvalued.
Does BioLight Life Sciences Ltd. pay dividends?
BioLight Life Sciences Ltd. does not currently pay dividends.
What is BioLight Life Sciences Ltd.’s EPS estimate?
BioLight Life Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioLight Life Sciences Ltd. have?
BioLight Life Sciences Ltd. has 9,079,270 shares outstanding.
What happened to BioLight Life Sciences Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioLight Life Sciences Ltd.?
Currently, no hedge funds are holding shares in IL:BOLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioLight Life Sciences Ltd.
BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of product candidates include DiagnosTear's TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops; ViSci, an Eye D technology that treats glaucoma by the insertion of a sub conjunctival implant; OphRx that develops drugs for treating eye diseases; and Peripherex, which develops solutions for at-home and in-office diagnosis and monitoring of peripheral vision impairment used by eye care and other providers to diagnose and monitor glaucoma and other diseases. Its pipeline also include AEYE that develops artificial intelligence solutions for a variety of retinal diseases; Tarsier, which develops TRS 01 based on its technological platform for the treatment of Uveitis in patients suffering from high IPO; Belkin Vision that develops clinic fast and automatic laser device to enable glaucoma patients to receive short & effective treatments as treatment to lower IOP; and Sanoculis, which develops an innovative surgical procedure for the treatment of the Glaucoma. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016. BioLight Life Sciences Ltd. was incorporated in 2005 and is based in Tel Aviv, Israel.